193 related articles for article (PubMed ID: 10650781)
1. Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage IB cervical cancer.
Moser PL; Kieback DG; Hefler L; Tempfer C; Neunteufel W; Gitsch G
Anticancer Res; 1999; 19(5C):4391-3. PubMed ID: 10650781
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage I and II endometrial cancer.
Moser PL; Hefler L; Tempfer C; Neunteufel W; Kieback DG; Gitsch G
Anticancer Res; 1999; 19(3B):2365-7. PubMed ID: 10472357
[TBL] [Abstract][Full Text] [Related]
3. [Expression of matrix metalloproteinase-2, 9 and their inhibitor-TIMP 1,2 in human squamous cell carcinoma of uterine cervix].
Zhou CY; Yao JF; Chen XD
Ai Zheng; 2002 Jul; 21(7):735-9. PubMed ID: 12479097
[TBL] [Abstract][Full Text] [Related]
4. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical detection of membrane-type-1-matrix metalloproteinase in colorectal carcinoma.
Kikuchi R; Noguchi T; Takeno S; Kubo N; Uchida Y
Br J Cancer; 2000 Jul; 83(2):215-8. PubMed ID: 10901373
[TBL] [Abstract][Full Text] [Related]
6. [Expression and clinical significance of MMP-2, MMP-9,TIMP-1, and TIMP-2 in breast carcinoma].
Fan SQ; Wei QY; Li MR; Zhang LQ; Liang QC
Ai Zheng; 2003 Sep; 22(9):968-73. PubMed ID: 12969531
[TBL] [Abstract][Full Text] [Related]
7. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
8. [Expression of matrix metaloproteinase and tissue inhibitors in ovarian tumors].
Cai W; Song JD
Ai Zheng; 2002 Jan; 21(1):91-4. PubMed ID: 12500407
[TBL] [Abstract][Full Text] [Related]
9. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
Sakata K; Shigemasa K; Nagai N; Ohama K
Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
[TBL] [Abstract][Full Text] [Related]
10. [Expression of matrix metalloproteinase-2, 9 and it's tissue inhibitor-1, 2 in endometrial carcinoma].
Guo W; Chen G; Zhu C; Wang H
Zhonghua Fu Chan Ke Za Zhi; 2002 Oct; 37(10):604-7. PubMed ID: 12487935
[TBL] [Abstract][Full Text] [Related]
11. [Prognostic value of stromal immunolabelling by MMP-2, MT1-MMP and TIMP-2 in clinically localized prostate cancer].
Semaan M; Jovenin N; Birembaut P; Menard J; Staerman F
Prog Urol; 2005 Apr; 15(2):250-4. PubMed ID: 15999602
[TBL] [Abstract][Full Text] [Related]
12. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G
Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326
[TBL] [Abstract][Full Text] [Related]
13. Quantitative estimation of matrix metalloproteinases 2 and 7 (MMP-2, MMP-7) and tissue inhibitors of matrix metalloproteinases 1 and 2 (TIMP-1, TIMP-2) in colorectal carcinoma tissue samples.
Pesta M; Holubec L; Topolcan O; Cerna M; Rupert K; Holubec LS; Treska V; Kormunda S; Elgrova L; Finek J; Cerny R
Anticancer Res; 2005; 25(5):3387-91. PubMed ID: 16101153
[TBL] [Abstract][Full Text] [Related]
14. Expression of matrix metalloproteinase 2 and its tissue inhibitor in oral squamous cell carcinoma.
Gao ZB; Duan YQ; Zhang L; Chen DW; Ding PT
Int J Mol Med; 2005 Oct; 16(4):599-603. PubMed ID: 16142392
[TBL] [Abstract][Full Text] [Related]
15. [Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the hepatocellular carcinomas].
Wei QY; Wu YQ; Fan SQ
Hunan Yi Ke Da Xue Xue Bao; 2003 Jun; 28(3):212-6. PubMed ID: 14653069
[TBL] [Abstract][Full Text] [Related]
16. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
[TBL] [Abstract][Full Text] [Related]
17. [The expression of matrix metalloproteinase-2 and -9 in cervical cancer and a study of their relationship].
Ouyang YW; Peng ZL; Yao XY; Liu SL; He YD
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 May; 35(3):330-3. PubMed ID: 15181827
[TBL] [Abstract][Full Text] [Related]
18. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in uterine endometrial carcinoma and a correlation between expression of matrix metalloproteinase-7 and prognosis.
Misugi F; Sumi T; Okamoto E; Nobeyama H; Hattori K; Yoshida H; Matsumoto Y; Yasui T; Honda K; Ishiko O
Int J Mol Med; 2005 Oct; 16(4):541-6. PubMed ID: 16142384
[TBL] [Abstract][Full Text] [Related]
19. [Assay of matrix metalloproteinase levels and their endogenous inhibitors in patients with laryngeal carcinoma].
Klisho EV; Savenkova OV; Kondakova IV; Perel'muter VM; Choĭnzonov EL; Shishkin DA
Vopr Onkol; 2007; 53(1):26-31. PubMed ID: 17649730
[TBL] [Abstract][Full Text] [Related]
20. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer.
Murray GI; Duncan ME; O'Neil P; McKay JA; Melvin WT; Fothergill JE
J Pathol; 1998 Jul; 185(3):256-61. PubMed ID: 9771478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]